golf is Resverlogix not responding to Long-Covid by the following:

"CORAL Study Design

The Phase 3, multicenter, randomized clinical trial, entitled: A Double-Blind Placebo Controlled Study to Assess the Efficacy and Safety of Oral Apabetalone in Elderly Subjects with Covid-19 Infection and High Risk for Severe Illness and to Explore the Potential to Limit Long-Term Symptoms(CORAL), will evaluate the safety and efficacy of apabetalone in preventing serious health outcomes in high-risk COVID-19 patients. Study site selection is currently underway, with sites expected in the United States, Canada, and the Middle East.

“We are just starting to understand the serious, long-term, cardiovascular consequences of the COVID-19 pandemic,” said Dr. Barry S. Zingman, M.D., Clinical Director, Infectious Diseases at the Montefiore Medical Center – Moses Division, Professor of Medicine at the Albert Einstein College of Medicine, and a member of Resverlogix’s COVID-19 Scientific Advisory Board. “Emerging therapies, such as apabetalone, have the potential to help address the critical unmet need in these patients.”

High-risk COVID-19 Patients

A recently published, large-scale analysis of electronic health records, found that individuals who have contracted COVID-19 are at significantly greater long-term risk for a broad range of negative cardiovascular outcomes, including acute coronary disease, heart attack, stroke, and heart failure, compared to those who had never had the disease1. The study found elevated risks persisted long after the initial infection, even in people who were not hospitalized for COVID-19, and were most pronounced among high-risk patients – including those with a history of cardiovascular disease, those with pre-existing comorbidities and those over the age of 65."

Would the "Phase 3, CORAL Study" not be a quicker way in finding out if Apabetalone works in this regard?

Koo